Hyperuricemia as a marker of chronic systemic inflammation in the pathogenesis of psoriasis

Background. The psoriasis (Ps) pathogenesis is complex and multifaceted; it is of particular interest for study, since its clinical diversity increases annually and the number of patients with resistance to the therapy grows. Ps is a chronic systemic immune-mediated disease characterized not only by skin changes, but also by an increased risk of developing concomitant diseases, such as psoriatic arthritis, cardiovascular diseases, diabetes mellitus, obesity, and inflammatory bowel diseases. The trigger for the development of these diseases is chronic systemic inflammation, which is recognized as the main cause of many “diseases of civilization” (modern diseases). Patients with Ps often have hyperuricemia (increased uric acid levels, an inflammation marker), the decrease in which leads to an easing of symptoms in patients. Understanding the relationship between chronic systemic inflammation and hyperuricemia and their impact on the severity of Ps and the development of complications can contribute to the development of effective treatment strategies and improving the quality of life of patients who are difficult to treat. The relationship between Ps and hyperuricemia is associated with a common pathogenesis, which covers both inflammatory and metabolic disorders.

Conclusion. Analysis of modern scientific research proves the role of hyperuricemia as a marker of chronic systemic inflammation in the pathogenesis of Ps. Inhibition of uric acid production and reduction of inflammation are potential therapeutic strategies for improving the quality of life of patients with Ps. Further study of specific mechanisms is required.